The Croda commitment and purpose

As a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, we are committed to enabling the next generation of drug delivery systems. As a business, we are focused on empowering biologics drug delivery, through our adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, our pharmaceutical portfolio is unsurpassed in its excellence for drug and vaccine delivery. Our products, along with our in-house formulation and regulatory expertise, allow us to meet our customers most demanding formulation needs.

Driving a sustainable future

As a part of Croda, our purpose is to use Smart science to improve lives™, enabled by our distinctive values-led culture that governs how we work with one another and guides our relationships with all of our partners. We combine our knowledge, passion and entrepreneurial spirit to create, make and sell speciality ingredients that are relied on by industries and consumers everywhere. 

Driving the pipeline of vaccines for 2024

We are proud to contribute to our target milestone for 2024, which is to ensure our technology will be part of at least 10 clinical phase III trials for at least 25% of the WHO listed pipeline vaccines. Despite the acceleration of the vaccine development cycle driven by the critical requirements to develop a vaccine for COVID-19, the ongoing ‘baseline’ for current clinical trials across the WHO priority diseases is currently in low single figures. For our products to be included in 10 clinical trials during 2024 sets us a significant challenge for the next few years.